8-K: VolitionRx Reports Mid-Year Progress, Expands Global Reach of Nu.Q Vet Cancer Test

VolitionRx has expanded the availability of its Nu.Q Vet Cancer Test to 15 countries and is preparing for licensing deals in the human space.

Summary

• VolitionRx has made significant progress in the first half of 2024, particularly with the expansion of its Nu.Q Vet Cancer Test.
• The test is now available in 15 countries through various veterinary diagnostic providers, including Antech, IDEXX, and Fujifilm Vet Systems.
• Volition has received $23 million in upfront and milestone payments from Heska related to the Nu.Q Vet Cancer Test.
• Antech has launched the test in several major markets since April 2024, with further expansion planned.
• The Nu.Q Vet Cancer Test is rapid, accurate, and cost-effective, costing only $35 to the vet.
• In 2023, Volition sold 58,000 Nu.Q Vet Cancer Tests at an average revenue of $8 per test, and aims to triple this number in 2024.
• Volition is also advancing its Nu.Q NETs product for sepsis and cancer detection technologies, preparing them for licensing.
• The company is preparing data rooms for licensing opportunities for Nu.Q NETs, Nu.Q Lung, and Capture-PCR technologies.
• Volition is in active commercial discussions with several companies, including those in liquid biopsy, diagnostics, and IVD.
• The company's focus is on low capital expenditures for partners and low operating expenses for Volition, with the goal of low-cost and accessible tests worldwide.
• Volition is developing a low-cost test for sepsis risk stratification and monitoring, with studies expected to be published in late 2024.
• Volition's cancer research is focused on lung cancer, aiming to develop a low-cost test for early detection, treatment tailoring, and monitoring.
• The company has developed a novel Capture-PCR method for direct detection of cancer-derived ctDNA, which could be a breakthrough in liquid biopsies.
• Volition plans to submit the Capture-PCR method and results for publication in a peer-reviewed journal in July 2024.

Sentiment

Score: 8

Explanation: The document conveys a positive outlook with significant progress in commercialization and technology development. The company has achieved key milestones and is actively pursuing licensing opportunities. There are risks, but the overall tone is optimistic.

Positives

• The Nu.Q Vet Cancer Test has seen significant expansion and is now available in 15 countries.
• The company has secured $23 million in upfront and milestone payments from Heska.
• The Nu.Q Vet Cancer Test is rapid, accurate, and cost-effective.
• Volition is actively preparing for licensing deals in the human space.
• The Capture-PCR technology has the potential to be a breakthrough in liquid biopsies.
• Volition has a strong intellectual property portfolio and is actively seeking commercialization opportunities.

Negatives

• The document does not explicitly mention any negatives, but it does highlight the risks associated with forward-looking statements.
• The company is still in the process of commercializing its technologies and securing licensing agreements.

Risks

• The company's actual results may differ materially from forward-looking statements due to various risks and uncertainties.
• There is a risk that the marketplace may not accept Volition's products.
• The company faces fierce competition in the diagnostics and disease monitoring markets.
• Volition may fail to secure adequate intellectual property protection.
• The company may fail to obtain necessary regulatory clearances or approvals.
• Downturns in domestic and foreign economies could impact the company's performance.

Future Outlook

Volition's focus in the second half of 2024 includes negotiating its first licensing deal in the human space, following a similar approach to the veterinary space. The company aims to broadly license its technologies and execute agreements in the future.

Management Comments

• Cameron Reynolds, President and Group Chief Executive Officer, stated that the company has successfully supported its veterinary licensing and distribution partners to launch the Nu.Q Vet Cancer test.
• Cameron Reynolds also mentioned that the company has progressed its Nu.Q NETs product for sepsis, Nu.Q Lung Cancer and Capture-PCR technologies to be ready for licensing.
• Cameron Reynolds believes the company has made great progress in its mission throughout the first half of 2024 and has several significant commercial opportunities ready for commercialization through licensing.

Industry Context

Volition's focus on early disease detection and monitoring aligns with the broader industry trend towards personalized medicine and preventative healthcare. The company's development of low-cost, accessible tests addresses a key need in the market. The company is competing with other liquid biopsy and diagnostic companies.

Comparison to Industry Standards

• The Nu.Q Vet Cancer Test's 76% sensitivity and 97% specificity are competitive with other cancer detection tests in the veterinary market.
• The company's Capture-PCR technology, if successful, could be a significant advancement over current liquid biopsy methods, which are often expensive and time-consuming.
• The company's focus on low-cost tests aligns with the industry's push for more accessible healthcare solutions.
• Competitors in the liquid biopsy space include companies like Guardant Health and Exact Sciences, which focus on human cancer detection. Volition's approach is unique in that it is focusing on both human and animal health.

Stakeholder Impact

• Shareholders will benefit from the company's progress in commercialization and technology development.
• Veterinarians and pet owners will have access to a rapid, accurate, and cost-effective cancer detection test.
• Patients may benefit from the development of new diagnostic and monitoring tools for cancer and sepsis.
• Licensing partners will have access to Volition's innovative technologies.

Next Steps

• Negotiate first licensing deal in the human space.
• Open data rooms for Nu.Q NETs, Nu.Q Lung, and Capture-PCR technologies.
• Submit Capture-PCR method and results for publication.
• Continue discussions with National Screening programs.
• Expand the availability of the Nu.Q Vet Cancer Test to more countries.

Key Dates

Keywords

Nu.Q Vet Cancer Test, Capture-PCR, Licensing, Liquid Biopsy, Sepsis, Cancer Detection, Epigenetics, Diagnostics, VolitionRx, Nu.Q NETs